Efficacy, long-term safety, and tolerability of Ziprasidone in children and adolescents with bipolar disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 8, 2013, Pages 545-557

  Findling, Robert L ^a   Çavuş, Idil ^b   Pappadopulos, Elizabeth ^b   Vanderburg, Douglas G ^b   Schwartz, Jeffrey H ^b   Gundapaneni, Balarama K ^b   Delbello, Melissa P ^c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIPRASIDONE;

ABDOMINAL DISCOMFORT; ABNORMAL LABORATORY RESULT; ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; AKATHISIA; ARTICLE; AUTOMUTILATION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BLURRED VISION; BODY MASS; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CONGENITAL MALFORMATION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DELUSION; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENITIS; DYSKINESIA; DYSPHAGIA; DYSTONIA; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERACTIVITY; HYPERPROLACTINEMIA; INSOMNIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MANIA; MIXED MANIA AND DEPRESSION; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL STIFFNESS; NAUSEA; NOSE OBSTRUCTION; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; PARANOIA; POST HOC ANALYSIS; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; RISK ASSESSMENT; SCHOOL CHILD; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TACHYCARDIA; TREATMENT DURATION; TREMOR; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; YOUNG MANIA RATING SCALE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PIPERAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 84885999920     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0029     Document Type: Article

References (43)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
3. Baptista T, De MS, Beaulieu S, Bermudez A, Martinez M: The metabolic syndrome during atypical antipsychotic drug treatment: Mechanisms and management. Metab Syndr Relat Disord 2:290-307, 2004.
4. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676, 1989.
5. Blader JC, Carlson GA: Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996-2004.Biol Psychiatry 62:107-114, 2007.
6. Brotman MA, Kassem L, Reising MM, Guyer AE, Dickstein DP, Rich BA, Towbin KE, Pine DS, McMahon FJ, Leibenluft E: Parental diagnoses in youth with narrow phenotype bipolar disorder or severe mood dysregulation. Am J Psychiatry 164:1238-1241, 2007.
7. Chang KD: The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry 69 Suppl 4:4-8, 2008.
8. Correll CU: Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 20:195-201, 2008.
9. Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 46:687-700, 2007.
10. Craig TJ, Grossman S, Mojtabai R, Gibson PJ, Lavelle J, Carlson GA, Bromet EJ: Medication use patterns and 2-year outcome in firstadmission bipolar disorder with psychotic features. Bipolar Disord 6:406-415, 2004.
11. DelBello MP, Correll CU: Primum non nocere: Balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder. Bipolar Disord 12:113-115, 2010.
12. DelBello MP, Versavel M, Ice K, Keller D, Miceli J: Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol 18:491-499, 2008.
13. Findling RL, Gracious BL, McNamara NK, Youngstrom EA, Demeter CA, Branicky LA, Calabrese JR: Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord 3:202-210, 2001.
14. Findling RL, Youngstrom EA, McNamara NK, Stansbrey RJ, Demeter CA, Bedoya D, Kahana SY, Calabrese JR: Early symptoms of mania and the role of parental risk. Bipolar Disord 7:623-634, 2005.
15. Fristad MA, Weller RA, Weller EB: The Mania Rating Scale (MRS): Further reliability and validity studies with children. Ann Clin Psychiatry 7:127-132, 1995.
16. Geller B, Tillman R, Bolhofner K, Zimerman B: Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome. Arch Gen Psychiatry 65:1125-1133, 2008.
17. Geller B, Warner K, Williams M, Zimerman B: Prepubertal and young adolescent bipolarity versus ADHD: Assessment and validity using the WASH-U-KSADS, CBCL and TRF. J Affect Disord 51:93-100, 1998.
18. Geller B, Zimerman B, Williams M, DelBello MP, Bolhofner K, Craney JL, Frazier J, Beringer L, Nickelsburg MJ: DSM-IV mania symptoms in a prepubertal and early adolescent bipolar disorder phenotype compared to attention-deficit hyperactive and normal controls. J Child Adolesc Psychopharmacol 12:11-25, 2002a.
19. Geller B, Zimerman B, Williams M, DelBello MP, Frazier J, Beringer L: Phenomenology of prepubertal and early adolescent bipolar disorder: Examples of elated mood, grandiose behaviors, decreased need for sleep, racing thoughts and hypersexuality. J Child Adolesc Psychopharmacol 12:3-9, 2002b.
20. Guy W: ECDEU Assessment Manual for Psychopharmacology - Revised. Rockville, MD: United States Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMS Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
21. Henderson DC, Doraiswamy PM: Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 69 Suppl 1:32-44, 2008.
22. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
23. Keck PE, Jr., Versiani M, Potkin S, West SA, Giller E, Ice K: Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 160:741-748, 2003.
24. Keck PE, Jr., Versiani M, Warrington L, Loebel AD, Horne RL: Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J Clin Psychiatry 70:844-851, 2009.
25. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M: Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:213-235, 2005.
26. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL: 2000 CDC Growth Charts for the United States: Methods and development. Vital Health Stat 11:1-190, 2002.
27. Leibenluft E, Rich BA: Pediatric bipolar disorder. Annu Rev Clin Psychol 4:163-187, 2008.
28. Leverich GS, Post RM, Keck PE, Jr., Altshuler LL, Frye MA, Kupka RW, Nolen WA, Suppes T, McElroy SL, Grunze H, Denicoff K, Moravec MK, Luckenbaugh D: The poor prognosis of childhoodonset bipolar disorder. J Pediatr 150:485-490, 2007.
29. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM: The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 31:281-294, 1994.
30. McClellan J, Kowatch R, Findling RL: Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 46:107-125, 2007.
31. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A: The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 60:497-502, 2003.
32. Pfeifer JC, Kowatch RA, DelBello MP: The use of antipsychotics in children and adolescents with bipolar disorders. Expert Opin Pharmacother 8:2673-2687, 2007.
33. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDAs pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043, 2007.
34. Potkin SG, Keck PE, Jr., Segal S, Ice K, English P: Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo- controlled replication trial. J Clin Psychopharmacol 25:301-310, 2005.
35. Poznanski EO, Mokros HB: Childrens Depression Rating Scale, Revised Manual. Los Angeles: Western Psychological Services; 1996.
36. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A childrens global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
37. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19, 1970.
38. Singh MK, DelBello MP, Kowatch RA, Strakowski SM: Co-occurrence of bipolar and attention-deficit hyperactivity disorders in children. Bipolar Disord 8:710-720, 2006.
39. Stewart M, DelBello MP, Versavel M, Keller D: Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol 19:635-640, 2009.
40. Sussman N: The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 23:S21-S26, 2003.
41. Warrington L, Lombardo I, Loebel A, Ice K: Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS Drugs 21:835-849, 2007.
42. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133: 429-435, 1978.
43. Youngstrom EA, Danielson CK, Findling RL, Gracious BL, Calabrese JR: Factor structure of the Young Mania Rating Scale for use with youths ages 5 to 17 years. J Clin Child Adolesc Psychol 31:567-572, 2002.